ABMD - Abiomed shares fall as med tech lowers 2022 revenue guidance

• Abiomed ( NASDAQ: ABMD ) is down 4% in Thursday afternoon trading after the medical technology company lowered its full-year revenue guidance due to impacts from foreign exchange rates.
• At its low today, the heart pump maker was down ~7% , the biggest intraday drop since May.
• Abiomed ( ABMD ) is now guiding to fiscal 2023 revenue of $1.13B to $1.17B. The analyst consensus for FY 23 is $1.16B.
• The company did beat on the top and bottom lines for FQ1 23.
• BTIG analyst Marie Thibault, who maintained a neutral rating on Abiomed ( ABMD ), wrote Thursday that "we think the company deserves recognition for the strength of the cardiogenic shock and Impella 5.5 businesses, its cash flow generation, and flexible, shored-up balance sheet."
• In a just published analysis, Seeking Alpha contributor Hummingbird Insights has a buy rating and $388 price target .

For further details see: